(PLRX) Pliant Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7291391057

Fibrosis, Liver Disease, Muscular Dystrophy, Solid Tumors

PLRX EPS (Earnings per Share)

EPS (Earnings per Share) of PLRX over the last years for every Quarter: "2020-03": 0.35, "2020-06": -1.39, "2020-09": -0.47, "2020-12": -0.54, "2021-03": -0.64, "2021-06": -0.64, "2021-09": -0.75, "2021-12": -0.68, "2022-03": -0.77, "2022-06": -0.82, "2022-09": -0.6, "2022-12": -0.71, "2023-03": -0.5, "2023-06": -0.7, "2023-09": -0.7, "2023-12": -0.69, "2024-03": -0.78, "2024-06": -0.92, "2024-09": -0.95, "2024-12": -0.82, "2025-03": -0.92,

PLRX Revenue

Revenue of PLRX over the last years for every Quarter: 2020-03: 28.938, 2020-06: 3.6, 2020-09: 4.814, 2020-12: 4.465, 2021-03: 2.174, 2021-06: 1.789, 2021-09: 1.61, 2021-12: 1.999, 2022-03: 1.249, 2022-06: 4.989, 2022-09: 1.482, 2022-12: 1.965, 2023-03: 1.332, 2023-06: 0.248, 2023-09: 0, 2023-12: 4.839998, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0,

Description: PLRX Pliant Therapeutics

Pliant Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for fibrotic diseases and related conditions. The companys pipeline is centered around its lead candidate, bexotegrast, a dual selective inhibitor targeting specific integrins, which has shown promise in treating primary sclerosing cholangitis and is currently in phase 2a trials. Additionally, Pliant Therapeutics is advancing other potential therapies, including PLN-1474 for liver fibrosis associated with nonalcoholic steatohepatitis, PLN-101095 for solid tumors, and PLN-101325 for muscular dystrophies, such as Duchenne muscular dystrophy.

The companys therapeutic approach is grounded in its understanding of the role of integrins in fibrosis and related diseases. By targeting specific integrins, Pliant Therapeutics aims to modulate the fibrotic process, potentially offering new treatment options for patients with limited or no effective therapies available. The progress of its lead candidate and other pipeline assets will be crucial in determining the companys future prospects.

Analyzing the , the stocks current price is $1.38, with its SMA20 and SMA50 indicating a short-term downtrend, while the SMA200 at $9.14 suggests a significant long-term decline. The ATR indicates a daily volatility of 8.31%, reflecting the stocks sensitivity to market fluctuations. Given the 52-week high of $15.70 and low of $1.23, the stock has shown considerable volatility. From a technical standpoint, a breakout above the SMA20 and SMA50 could signal a potential reversal, with a target near $1.60-$1.70. However, failure to sustain above these levels may lead to further decline.

Considering the , Pliant Therapeutics has a market capitalization of $97.60M USD, with no P/E ratio due to its current lack of profitability, reflected in a negative RoE of -56.84%. The absence of a forward P/E ratio further indicates that the company is not expected to be profitable in the near future. The current market cap and lack of earnings suggest that the stocks value is largely speculative, driven by the potential success of its pipeline assets. A key catalyst for the stock could be positive results from ongoing or future clinical trials, particularly for bexotegrast.

Forecasting the stocks performance using both and , a potential short-term trading opportunity may arise if the stock can break through its current resistance levels. However, the long-term outlook remains heavily dependent on the success of its clinical trials and the subsequent commercialization of its therapies. If bexotegrast or other pipeline assets show significant promise, we could see a substantial increase in the stock price, potentially targeting the $5-$7 range in the medium term, assuming successful phase 2b or phase 3 trials. Conversely, failure in clinical trials could lead to a decline towards the 52-week low.

Additional Sources for PLRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

PLRX Stock Overview

Market Cap in USD 77m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2020-06-03

PLRX Stock Ratings

Growth Rating -83.8
Fundamental -58.6
Dividend Rating 0.0
Rel. Strength -86.4
Analysts 3.23 of 5
Fair Price Momentum 0.87 USD
Fair Price DCF -

PLRX Dividends

Currently no dividends paid

PLRX Growth Ratios

Growth Correlation 3m -46.4%
Growth Correlation 12m -78.3%
Growth Correlation 5y -65.4%
CAGR 5y -42.72%
CAGR/Max DD 5y -0.44
Sharpe Ratio 12m 0.44
Alpha -101.69
Beta 1.165
Volatility 116.83%
Current Volume 845.6k
Average Volume 20d 1018.2k
Stop Loss 1.3 (-7.1%)
What is the price of PLRX shares?
As of July 12, 2025, the stock is trading at USD 1.40 with a total of 845,589 shares traded.
Over the past week, the price has changed by +11.11%, over one month by -9.09%, over three months by +11.55% and over the past year by -87.38%.
Is Pliant Therapeutics a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, Pliant Therapeutics (NASDAQ:PLRX) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -58.56 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PLRX is around 0.87 USD . This means that PLRX is currently overvalued and has a potential downside of -37.86%.
Is PLRX a buy, sell or hold?
Pliant Therapeutics has received a consensus analysts rating of 3.23. Therefor, it is recommend to hold PLRX.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 11
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for PLRX share price target?
According to our own proprietary Forecast Model, PLRX Pliant Therapeutics will be worth about 1 in July 2026. The stock is currently trading at 1.40. This means that the stock has a potential downside of -29.29%.
Issuer Target Up/Down from current
Wallstreet Target Price 4.8 242.1%
Analysts Target Price 10.1 618.6%
ValueRay Target Price 1 -29.3%